Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

Jonathan Pan,Sushil Ghimire,S. Onder Alpdogan,Andrew E. Chapman,Matthew Carabasi,Martina DiMeglio,Jerald Z. Gong,Ubaldo Martinez-Outschoorn,Lewis J. Rose,Michael Ramirez,John L. Wagner,Mark Weiss,Neal Flomenberg,Barbara Pro,Pierluigi Porcu,Joanne Filicko-OHara,Sameh Gaballa

Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

2020

Jonathan Pan
Sushil Ghimire
S. Onder Alpdogan
Andrew E. Chapman
Matthew Carabasi
Martina DiMeglio
Jerald Z. Gong
Ubaldo Martinez-Outschoorn
Lewis J. Rose
Michael Ramirez
John L. Wagner
Mark Weiss
Neal Flomenberg
Barbara Pro
Pierluigi Porcu
Joanne Filicko-OHara
Sameh Gaballa

We developed an outpatient salvage chemotherapy regimen using bendamustine, ofatumumab, carboplatin and etoposide (BOCE) to treat relapsed/refractory non-Hodgkin lymphoma (RR NHL) in a single-cente...

Keywords:

Bendamustine
Lymphoma
Etoposide
Internal medicine
Ofatumumab
B-Cell Non-Hodgkin Lymphoma
Oncology
Medicine
Refractory
Carboplatin
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations